- Pfizer's and Moderna's vaccines likely work for all existing coronavirus strains. Don't worry about mutations for now, scientists say - 1 Update
- The Virus Won't Stop Evolving When the Vaccine Arrives - 1 Update
- Pfizer-BioNTech hopes to be able to manufacture up to 1.3 billion doses in 2021 and Moderna says it is optimistic about producing 500 million to one billion doses in the next year - 1 Update
- Coronavirus mutations under the magnifying glass of scientists - 1 Update
| Amine Moulay Ramdane <aminer68@gmail.com>: Dec 04 10:11AM -0800 Hello, Don't worry about mutated strains of the coronavirus, experts say — the leading vaccine candidates should protect you against every version of the virus they've seen. Moderna and Pfizer each announced this month that their coronavirus vaccines prevent COVID-19 — the former's is 94.5% effective, while the latter's is 95%. Both companies hope to get approval from the FDA in the coming weeks. Genetic evidence about the virus so far suggests that these vaccine candidates — and others in the race — are unlikely to need much tweaking in the future. That's because the coronavirus, SARS-CoV-2, mutates slowly — its genome remains relatively stable over time. So any vaccine developed to target the original virus should work in the long-run against different versions that arise as it subtly evolves over time. Read more here: Pfizer's and Moderna's vaccines likely work for all existing coronavirus strains. Don't worry about mutations for now, scientists say https://www.businessinsider.com/coronavirus-vaccines-should-work-for-all-strains-mutations-2020-11 Thank you, Amine Moulay Ramdane. |
| Amine Moulay Ramdane <aminer68@gmail.com>: Dec 04 09:01AM -0800 Hello.. Read the following interesting article from New York times: The Virus Won't Stop Evolving When the Vaccine Arrives Read more here: https://www.nytimes.com/2020/11/27/science/covid-vaccine-virus-resistance.html Thank you, Amine Moulay Ramdane. |
| Amine Moulay Ramdane <aminer68@gmail.com>: Dec 04 08:42AM -0800 Hello.. Pfizer-BioNTech hopes to be able to manufacture up to 1.3 billion doses in 2021 and Moderna says it is optimistic about producing 500 million to one billion doses in the next year. Moderna revealed on Monday the results obtained two weeks after the administration of the second dose of his vaccine. Of the 30,000 people who took part in the clinical trial, 196 exhibited symptoms of COVID-19 and tested positive following a drug test. Of these 196 cases, 185 had received a placebo, which was given to half of the volunteers. None of the 11 cases of COVID-19 that occurred in the vaccinated group, however, suffered from the severe form of the infection, while 30 of the 185 cases in the placebo group were severely affected and one participant even succumbed to his illness. infection. These data therefore mean that the vaccine's effectiveness in preventing COVID-19 was 94.1%, and its effectiveness in limiting serious infections was 100%.The company also said the vaccine's effectiveness was found to be comparable across all ages and in all ethnic communities. Canada's "secure" place in the vaccine access queue Read more here: https://translate.google.com/translate?hl=en&sl=auto&tl=en&u=https%3A%2F%2Fwww.ledevoir.com%2Fsociete%2Fscience%2F590727%2Fla-place-du-canada-securisee-dans-la-file-d-attente-pour-l-acces-aux-vaccins Thank you, Amine Moulay Ramdane. |
| Amine Moulay Ramdane <aminer68@gmail.com>: Dec 04 08:29AM -0800 Hello.. Coronavirus mutations under the magnifying glass of scientists Read more here: https://translate.google.com/translate?hl=en&sl=auto&tl=en&u=https%3A%2F%2Fwww.ledevoir.com%2Fsociete%2Fscience%2F590169%2Fmutations-sous-surveillance Thank you, Amine Moulay Ramdane. |
| You received this digest because you're subscribed to updates for this group. You can change your settings on the group membership page. To unsubscribe from this group and stop receiving emails from it send an email to comp.programming.threads+unsubscribe@googlegroups.com. |
No comments:
Post a Comment